Back
 APD  Vol.5 No.3 , August 2016
Comparison of the Analgesic Activity of Antiparkinsonian Aminoadamantane Derivatives Amantadine and Hemantane
Abstract: The efficacy of some aminoadamantane derivatives used as neurodegeneration treatments is due to their ability to block NMDA receptors. But this mechanism of pharmacological action can also produce analgesic activity. Analgesic properties of two aminoadamantanes, amantadine (20 mg/kg) and hemantane (20 mg/kg), which were uncompetitive NMDA receptor antagonists, were assessed in rodent models of pain induced by different pain stimuli (tail-flick test, acetic twitches test in mice and formalin test in rats). Additionally, the anti-inflammatory properties of hemantane and amantadine were evaluated in mice with acetic peritonitis and in rats with hind paw edema induced by formalin injection. The results of our study demonstrate that the analgesic activity of the 1-aminoadamantane amantadine differs from the 2-aminoadamantane hemantane. The analgesic activity of amantadine administered intraperitoneally was more pronounced in the case of acute thermal pain in mice compared to hemantane, and only amantadine had a significant analgesic effect on the acute early phase of formalin pain in rats induced by the effect of the algogen on the primary sensory afferents. Hemantane was more effective than amantadine for relieving pain produced by inflammation owing to its pronounced anti-inflammatory activity: only hemantane decreased the amount of acetic twitches in mice that received drugs orally and was effective in the tonic phase of formalin pain in rats.
Cite this paper: Ivanova, E. , Kapitsa, I. , Valdman, E. and Voronina, T. (2016) Comparison of the Analgesic Activity of Antiparkinsonian Aminoadamantane Derivatives Amantadine and Hemantane. Advances in Parkinson's Disease, 5, 50-60. doi: 10.4236/apd.2016.53007.
References

[1]   Wanka, L., Iqbalb, K. and Schreiner, P.R. (2013) The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives. Chemical Reviews, 113, 3516-3604.
http://dx.doi.org/10.1021/cr100264t

[2]   Crosby, N.J., Deane, K. and Clarke, C.E. (2003) Amantadine for Dyskinesia in Parkinson’s Ddisease. Cochrane Database of Systematic Reviews, 2, CD003467.

[3]   Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., and for the Amantadine Study Group (2010) Amantadine for Dyskinesias in Parkinson’s Disease: A Randomized Controlled Trial. PLoS ONE, 12, e15298.
http://dx.doi.org/10.1371/journal.pone.0015298

[4]   Schwab, R.S., England, A.C., Poskanzer, D.C. and Young, R.R. (1969) Amantadine in the Treatment of Parkinson’s Disease. JAMA, 208, 1168-1170. http://dx.doi.org/10.1001/jama.1969.03160070046011

[5]   Reisberg, B., Doody, R., St?ffler, A., Schmitt, F., Ferris, S., M?bius, H.J., and for the Memantine Study Group (2003) Memantine in Moderate-to-Severe Alzheimer’s Disease. The New England Journal of Medicine, 14, 1333-1341. http://dx.doi.org/10.1056/NEJMoa013128

[6]   Peskind, E.R., Potkin, S.G., Pomara, N., Ott, B.R., Graham, S.M., Olin, J.T. and McDonald, S. (2006) Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial. The American Journal of Geriatric Psychiatry, 14, 704-715.
http://dx.doi.org/10.1097/01.JGP.0000224350.82719.83

[7]   Wilcock, G., M?bius, H.J., St?ffler, A., and MMM 500 Group (2002) A Double-Blind, Placebo-Controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia (MMM500). International Clinical Psychopharmacology, 17, 297-305. http://dx.doi.org/10.1097/00004850-200211000-00005

[8]   Merello, M., Nouzeilles, M.I., Cammarota, A. and Leiguarda R. (1999) Effect of Memantine (NMDA Antagonist) on Parkinson’s Disease: A Double-Blind Crossover Randomized Study. Clinical Neuropharmacology, 22, 273-276.

[9]   Nerobkova, L.N., Val’dman, E.A., Voronina, T.A., Markina, N.V. and Sharkova, L.M. (2000) Effect of the New Aminoadamantane Derivative A-7 on the Parkinsonism Syndrome Manifestations Induced by the Systemic Administration of MPTP Neurotoxin. Eksperimental’naia i Klinicheskaia Farmakologiia, 63, 3-6.

[10]   Kapitsa, I.G., Ivanova, E.A., Nepoklonov, A.V., Kokshenev, I.I., Voronina, T.A. and Val’dman, E.A. (2011) Comparative Study of Amantadine and Hemantane Effects on Development of Levodopa-Induced Dyskinesia in Rat Model of Parkinsonian Syndrome. Eksperimental’naia i Klinicheskaia Farmakologiia, 74, 9-12.

[11]   Kornhuber, J., Bormann, J., Hubers, M., Rusche, K. and Riederer, P. (1991) Effects of the 1-Aminoadamantanes at the MK-801 Binding Site of the NMDA Receptor Gated Ion Channel: Human Postmortem Study. European Journal of Pharmacology, 206, 297-300.
http://dx.doi.org/10.1016/0922-4106(91)90113-V

[12]   Danysz, W., Parsons, C.G., Kornhuber, J., Schmidt, W.J. and Quack, G. (1997) Aminoadamantanes as NMDA Receptor Antagonists and Antiparkinsonian Agents—Preclinical Studies. Neuroscience & Biobehavioral Reviews, 21, 455- 468. http://dx.doi.org/10.1016/S0149-7634(96)00037-1

[13]   Elshanskaya, M.V., Sobolevskii, A.I., Val’dman, E.A. and Khodorov, B.I. (2001) Interaction of the New Adamantane Derivative A7—A Potential Antiparkinsonian Drug—with NMDA Receptor Channels. Eksperimental’naia i Klinicheskaia Farmakologiia, 64, 18-21.

[14]   Danysz, W., Parsons, C.G., Bresink, I. and Quack, G. (1995) A Revived Target for Drug Development? Glutamate in CNS Disorders. Drug News & Perspectives (DN&P), 8, 261-277.

[15]   Ikeda, H., Heinke, B., Ruscheweyh, R. and Sandkühler J. (2003) Synaptic Plasticity in Spinal Lamina I Projection Neurons that Mediate Hyperalgesia. Science, 299, 1237-1240.
http://dx.doi.org/10.1126/science.1080659

[16]   Ikeda, H., Stark, J., Fischer, H., Wagner, M., Drdla, R., J?ger, T. and Sandkühler, J. (2006) Synaptic Amplifier of Inflammatory Pain in the Spinal Dorsal Horn. Science, 312, 1659-1662.
http://dx.doi.org/10.1126/science.1127233

[17]   Liu, X.G. and Sandkühler, J. (1995) Long-Term Potentiation of C-Fiber-Evoked Potentials in the Rat Spinal Dorsal Horn Is Prevented by Spinal N-Methyl-D-Aspartic Acid Receptor Blockage. Neuroscience Letters, 191, 43-46. http://dx.doi.org/10.1016/0304-3940(95)11553-0

[18]   Latremoliere, A. and Woolf, C.J. (2009) Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. The Journal of Pain, 10, 895-926.
http://dx.doi.org/10.1016/j.jpain.2009.06.012

[19]   Amin, P. and Sturrock, N.D. (2003) A Pilot Study of the Beneficial Effects of Amantadine in the Treatment of Painful Diabetic Peripheral Neuropathy. Diabetic Medicine, 20, 114-118.
http://dx.doi.org/10.1046/j.1464-5491.2003.00882.x

[20]   Valdman, E.A., Ivanova, E.A., Kapitsa, I.G., Voronina, T.A., Alekseeva, S.V., Nepoklonov, A.V. (2015) A Compound for the Therapy of Pain and Inflammation in Neurodegenerative Diseases. Rus Patent No. 2559777.

[21]   Muhlack, S., Müsch, P., Konietzka, S., Woitalla, D., Przuntek, H. and Müller, T. (2010) Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics, 2, 313-320. http://dx.doi.org/10.3390/pharmaceutics2030313

[22]   Todorovic, S.M., Rastogi, A.J. and Jevtovic-Todorovic, V. (2003) Potent Analgesic Effects of Anticonvulsants on Peripheral Thermal Nociception in Rats. British Journal of Pharmacology, 140, 255-260. http://dx.doi.org/10.1038/sj.bjp.0705434

[23]   Caldwell, J.R. (1986) Efficacy and Safety of Diclofenac Sodium in Rheumatoid Arthritis Experience in the United States. The American Journal of Medicine, 80, 43-47. http://dx.doi.org/10.1016/0002-9343(86)90079-3

[24]   Akriviadis, E., Hatzigavriel, M., Kapnias, D., Kirimlidis, J., Markantas, A. and Garyfallos, A. (1997) Treatment of Biliary Colic with Diclofenac: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology, 113, 225-231. http://dx.doi.org/10.1016/S0016-5085(97)70099-4

[25]   Wober, W. (1999) Comparative Efficacy and Safety of Nimesulide and Diclofenac in Patients with Acute Shoulder, and a Meta-Analysis of Controlled Studies of Nimesulide. Rheumatology, 38, 33-38. http://dx.doi.org/10.1093/rheumatology/38.suppl_1.33

[26]   Val’dman, E.A. (2001) Development of a Pharmacologic Medication for the Pathogenic Therapy of Parkinsonism Based on the Analysis of the Mechanisms of Action of Aminoadamantane Derivatives. Habilitation Thesis, Zakusov Institute of Pharmacology, Moscow.

[27]   Ivanova, E.A., Nepoklonov, A.V., Kokshenev, I.I., Kapitsa, I.G., Voronina, T.A. and Val’dman, E.A. (2012) Study of Anticataleptic Activity of Hemantane Using Different Routs of Drug Administration and in Combination with Levodopa. Biomedicine, 1, 74-81.

[28]   Bhandage, A., Shevkar, K. and Undale, V. (2009) Evaluation of Antinociceptive Activity of Roots of Glycyrrhiza glabra Linn. Journal of Pharmacy Research, 2, 803-807.

[29]   Purnima, A., Koti, B.C., Thippeswamy, A.H.M., Jaji, M.S., Vishwantha Swamy, A.H.M., Kurhe, Y.V. and Jaffar Sadiq, A. (2010) Antiinflammatory, Analgesic and Antipyretic Activities of Mimusops elengi Linn. Indian Journal of Pharmaceutical Sciences, 72, 480-485. http://dx.doi.org/10.4103/0250-474X.73908

[30]   Voronina, T.A. and Guzevatykh, L.S. (2012) Methodological Instructions on the Study of Drugs’ Analgesic Activity. In: Mironov, A.N., Bunatyan N.D., Vasil'ev, A.N., et al., Eds., Guidance on Preclinical Study of New Pharmacological Substances, Part 1, Grif and K, Moscow, 197-217.

[31]   Brown, J.H., Kissel, J.W. and Lish, P.M. (1968) Studies on the Acute Inflammatory Response. I. Involvement of the Central Nervous System in Certain Models of Inflammation. Journal of Pharmacology and Experimental Therapeutics, 160, 231-242.

[32]   Shvarts, G. Ya. and Syabaev, R.D. (2012) Methodological Instructions on the Study of New Nonsteroidal Anti- Inflammatory Drugs. In: Mironov, A.N., Bunatyan N.D., Vasil'ev, A.N., et al., Eds., Guidance on Preclinical Study of New Pharmacological Substances, Part 1, Grif and K, Moscow, 746-758.

[33]   Lee, I.O. and Jeong, Y.S. (2002) Effects of Different Concentrations of Formalin on Paw Edema and Pain Behaviors in Rats. Journal of Korean Medical Science, 17, 81-85.
http://dx.doi.org/10.3346/jkms.2002.17.1.81

[34]   Bannon, A.W. and Malmberg, A.B. (2007) Models of Nociception: Hot-Plate, Tail-Flick, and Formalin Tests in Rodents. Current Protocols in Neuroscience.
http://dx.doi.org/10.1002/0471142301.ns0809s41

[35]   Park, B.Y., Park, S.H., Kim, W.M., Yoon, M.H. and Lee, H.G. (2010) Antinociceptive Effect of Memantine and Morphine on Vincristine-Induced Peripheral Neuropathy in Rats. The Korean Journal of Pain, 23, 179-185. http://dx.doi.org/10.3344/kjp.2010.23.3.179

[36]   Pasquini, S., Botta, L., Semeraro, T., Mugnaini, C., Ligresti, A., Palazzo, E., Maione, S., Di Marzo, V. and Corelli, F. (2008) Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo. Journal of Medicinal Chemistry, 51, 5075-5084.
http://dx.doi.org/10.1021/jm800552f

[37]   Banister, S.D., Wilkinson, S.M., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D. E., Glass, M., Connor, M., McGregor, I.S. and Kassiou, M. (2013) The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 4, 1081-1092. http://dx.doi.org/10.1021/cn400035r

[38]   Fresno, N., Pérez-Fernández, R., Goicoechea, C., Alkorta, I., Fernández-Carvajal, A., de la Torre-Martínez, R., Quirce, S., Ferrer-Montiel, A., Martín, M.I., Goya, P. and Elguero, J. (2014) Adamantyl Analogues of Paracetamol as Potent Analgesic Drugs via Inhibition of TRPA1. PLoS ONE, 9, e113841. http://dx.doi.org/10.1371/journal.pone.0113841

[39]   Battilocchio, C., Guetzoyan, L., Cervetto, C., Di Cesare Mannelli, L., Frattaroli, D., Baxendale, I.R., Maura, G., Rossi, A., Sautebin, L., Biava, M., Ghelardini, C., Marcoli, M. and Ley, S.V. (2013) Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release. ACS Medicinal Chemistry Letters, 4, 704-709.
http://dx.doi.org/10.1021/ml400079h

[40]   Zimin, I.A. (2011) Study of the Role of the Serotonergic Component in the Mechanism of Action of the Antiparkinsonian Drug Hemantane. PhD Thesis, Zakusov Institute of Pharmacology, Moscow.

[41]   Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. and Cenci, M.A. (2002) Pharmacological Validation of Behavioural Measures of Akinesia and Dyskinesia in a Rat Model of Parkinson’s Disease. European Journal of Neuroscience, 15, 120-132.
http://dx.doi.org/10.1046/j.0953-816x.2001.01843.x

[42]   Dekundy, A., Lundblad, M., Danysz, W. and Cenci, M.A. (2007) Modulation of L-DOPA-Induced Abnormal Involuntary Movements by Clinically Tested Compounds: Further Validation of the Rat Dyskinesia Model. Behavioural Brain Research, 179, 76-89.
http://dx.doi.org/10.1016/j.bbr.2007.01.013

[43]   Paquette, M.A., Martinez, A.A., Macheda, T., Meshul, C.K., Johnson, S.W., Berger, S.P. and Giuffrida, A. (2012) Anti-Dyskinetic Mechanisms of Amantadine and Dextromethorphan in the 6-OHDA Rat Model of Parkinson’s Disease: Role of NMDA vs. 5-HT1A Receptors. European Journal of Neuroscience, 36, 3224-3234. http://dx.doi.org/10.1111/j.1460-9568.2012.08243.x

[44]   Hunskaar, S. and Hole, K. (1987) The Formalin Test in Mice: Dissociation between Inflammatory and Non- Inflammatory Pain. Pain, 30, 103-114. http://dx.doi.org/10.1016/0304-3959(87)90088-1

[45]   Ivanova, E.A., Kapitsa, I.G., Valdman, E.A. and Voronina, T.A. (2013) The Activity of Antiparkinsonian Drug Hemantane in Models of Peripheral Inflammation and Lipopolysaccharide-Induced Neuroinflammation. Advances in Parkinson’s Disease, 2, 11-17.
http://dx.doi.org/10.4236/apd.2013.21003

[46]   Tallerova, A.V., Ivanova, E.A., Kapitsa, I.G., Kovalenko, L.P., Val’dman, E.A. and Voronina, T.A. (2013) Influence of Antiparkinsonian Drug Hemantane on the Level of Cytokines in Experimental Models. Immunologiya, 5, 254-257.

[47]   Valdman, E., Ivanova, E., Zolotov, N., Kapitsa, I. and Voronina, T. (2015) Effects of Hemantane upon the Activity of Proline-Specific Endopeptidases in Plasma of Rats with Experimental Parkinson’s Disease. Intrisic Activity, 3, A2.12.

[48]   Tenorio-Laranga, J., Montoliu, C., Urios, A., Hernandez-Rabaza, V., Ahabrach, H., García-Horsman, J.A. and Felipo, V. (2015) The Expression Levels of Prolyl Oligopeptidase Responds Not Only to Neuroinflammation but Also to Systemic Inflammation upon Liver Failure in Rat Models and Cirrhotic Patients. Journal of Neuroinflammation, 12, 183. http://dx.doi.org/10.1186/s12974-015-0404-7

[49]   Chattopadhyaya, I., Gupta, S., Mohammed, A., Mushtaq, N., Chauhan, S. and Ghosh, S. (2015) Neuroprotective Effect of Spirulina Fusiform and Amantadine in the 6-OHDA Induced Parkinsonism in Rats. BMC Complementary and Alternative Medicine, 15, 296. http://dx.doi.org/10.1186/s12906-015-0815-0

[50]   Ossola, B., Schendzielorz, N., Chen, S.H., Bird, G.S., Tuominen, R.K., M?nnist?, P.T. and Hong, J.S. (2011) Amantadine Protects Dopamine Neurons by a Dual Action: Reducing Activation of Microglia and Inducing Expression of GNDF in Astroglia. Neuropharmacology, 61, 574-582.
http://dx.doi.org/10.1016/j.neuropharm.2011.04.030

[51]   Stark, D.T. and Bazan, N.G. (2011) Synaptic and Extrasynaptic NMDA Receptors Differentially Modulate Neuronal Cyclooxygenase-2 Function, Lipid Peroxidation, and Neuroprotection. The Journal of Neuroscience, 31, 13710-13721. http://dx.doi.org/10.1523/JNEUROSCI.3544-11.2011

 
 
Top